Clover Health Investments (CLOV) Revenue & Revenue Breakdown
Clover Health Investments Revenue Highlights
Latest Revenue (Y)
$1.37B
Latest Revenue (Q)
$477.62M
Main Segment (Y)
Insurance
Main Geography (Y)
Direct Contracting Operations
Clover Health Investments Revenue by Period
Clover Health Investments Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $1.37B | -32.58% |
| 2023-12-31 | $2.03B | -41.50% |
| 2022-12-31 | $3.48B | 136.19% |
| 2021-12-31 | $1.47B | 118.76% |
| 2020-12-31 | $672.89M | 45.56% |
| 2019-12-31 | $462.27M | 64.49% |
| 2018-12-31 | $281.02M | - |
Clover Health Investments generated $1.37B in revenue during NA 2024, up -32.58% compared to the previous quarter, and up 296.61% compared to the same period a year ago.
Clover Health Investments Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $477.62M | 3.31% |
| 2025-03-31 | $462.33M | 37.21% |
| 2024-12-31 | $336.96M | 1.81% |
| 2024-09-30 | $330.99M | -7.09% |
| 2024-06-30 | $356.26M | 2.69% |
| 2024-03-31 | $346.92M | -32.01% |
| 2023-12-31 | $510.25M | 66.73% |
| 2023-09-30 | $306.03M | -4.41% |
| 2023-06-30 | $320.14M | -0.58% |
| 2023-03-31 | $321.99M | -64.17% |
| 2022-12-31 | $898.79M | 4.90% |
| 2022-09-30 | $856.82M | 1.19% |
| 2022-06-30 | $846.70M | -3.17% |
| 2022-03-31 | $874.38M | 102.39% |
| 2021-12-31 | $432.04M | 1.14% |
| 2021-09-30 | $427.16M | 3.56% |
| 2021-06-30 | $412.47M | 105.90% |
| 2021-03-31 | $200.32M | 20.51% |
| 2020-12-31 | $166.23M | -1.68% |
| 2020-09-30 | $169.07M | -1.75% |
| 2020-06-30 | $172.08M | 3.97% |
| 2020-03-31 | $165.50M | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2019-09-30 | $118.38M | 0.41% |
| 2019-06-30 | $117.91M | - |
| 2019-03-31 | $117.91M | - |
Clover Health Investments generated $477.62M in revenue during Q2 2025, up 3.31% compared to the previous quarter, and up 137.67% compared to the same period a year ago.
Clover Health Investments Revenue Breakdown
Clover Health Investments Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 21 |
|---|---|---|---|
| Insurance | $26.25M | $10.34M | - |
| Non-Insurance | - | $773.18M | - |
| Direct Contracting Operations | - | - | $667.64M |
Clover Health Investments's latest annual revenue breakdown by segment (product or service), as of Dec 24: Insurance (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insurance | $16.22M | $14.45M | $18.21M | $4.31M | $3.73M | $3.14M | $3.34M | $2.02M | $1.84M | $1.13M | $957.00K | $220.00K | $271.00K | - | - | - |
| Non-Insurance | - | - | - | - | - | $595.39M | $176.04M | $1.32M | $428.00K | $834.00K | $457.00K | $20.00K | - | - | - | - |
| Corporate and Other | - | - | - | - | - | - | - | - | - | - | $29.95M | $27.03M | $9.38M | $16.51M | - | - |
| Medicare Advantage Segment | - | - | - | - | - | - | - | - | - | - | - | - | - | $108.00K | - | - |
| Direct Contracting Segment | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Clover Health Investments's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Insurance (100.00%).
Clover Health Investments Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 21 |
|---|---|
| Direct Contracting Operations | $667.64M |
Clover Health Investments's latest annual revenue breakdown by geography, as of Dec 21: Direct Contracting Operations (100.00%).
Clover Health Investments Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TDOC | Teladoc Health | $2.57B | $631.90M |
| MD | Pediatrix Medical Group | $2.01B | $468.84M |
| CLOV | Clover Health Investments | $1.37B | $477.62M |
| GDRX | GoodRx | $792.32M | $202.97M |
| AZTA | Azenta | $656.32M | $143.94M |
| TXG | 10x Genomics | $610.78M | $154.88M |
| NVCR | NovoCure | $605.22M | $154.99M |
| BCRX | BioCryst Pharmaceuticals | $450.71M | $163.35M |
| PHR | Phreesia | $419.81M | $117.25M |
| SDGR | Schrödinger | $207.54M | $59.55M |
| OMDA | Omada Health | $169.80M | $54.96M |